Mark A. Socinski, MD

Articles

Dr. Socinski on New Applications of Immunotherapy in NSCLC

April 16th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer.

Dr. Socinski on Mechanisms of Resistance in Lung Cancer

March 26th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.

Dr. Socinski on Current State of Treatment in NSCLC

February 22nd 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.

Dr. Socinski on Immunotherapy Approaches in Squamous NSCLC

January 30th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.

Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

April 26th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Dr. Socinski on Milestone of Immunotherapy in Lung Cancer

March 6th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses the type of milestone that immunotherapy has had on the field of lung cancer.

Dr. Socinski on Recent Setbacks in Immunotherapy Combinations in NSCLC

February 7th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).

Dr. Socinski on Nivolumab in NSCLC

June 2nd 2015

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).

Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: Before We Accept This Treatment Paradigm, Let's Critically Evaluate and Interpret the Data

March 4th 2011

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States.